What’s Entasis Therapeutics Holdings Inc (NASDAQ:ETTX) Upside After This Short Interest Decrease?

The stock of Entasis Therapeutics Holdings Inc (NASDAQ:ETTX) registered a decrease of 0.22% in short interest. ETTX’s total short interest was 45,800 shares in May as published by FINRA. Its down 0.22% from 45,900 shares, reported previously. With 21,300 shares average volume, it will take short sellers 2 days to cover their ETTX’s short positions.

The stock decreased 0.30% or $0.02 during the last trading session, reaching $6.68. About 2,902 shares traded. Entasis Therapeutics Holdings Inc. (NASDAQ:ETTX) has 0.00% since May 17, 2018 and is . It has underperformed by 4.37% the S&P500.

Entasis Therapeutics Holdings Inc., a clinical-stage biopharmaceutical company, focuses on the discovery, development, and commercialization of novel antibacterial products to treat serious infections caused by multi-drug resistant gram-negative bacteria in the United States. The company has market cap of $87.71 million. It is involved in developing ETX2514SUL, a novel IV antibiotic that has completed Phase II clinical trial for the treatment of multi-drug resistant Acinetobacter infections; Zoliflodacin, an oral antibiotic monotherapy that has completed Phase II clinical trial for the treatment of uncomplicated gonorrhea; ETX0282CPDP, an oral drug that is in Phase I clinical trial for the treatment of urinary tract infections; and various antibiotics for gram-negative infections. It currently has negative earnings. The firm has collaboration agreements with Zai Lab Co., Ltd. and Drugs for Neglected Diseases initiative.

More notable recent Entasis Therapeutics Holdings Inc. (NASDAQ:ETTX) news were published by: Globenewswire.com which released: “Entasis Therapeutics Reports Third Quarter 2018 Financial Results and Provides Business Update – GlobeNewswire” on November 14, 2018, also Nasdaq.com with their article: “Entasis Therapeutics plummets 29% in worst biotech debut since 2002 – Nasdaq” published on September 26, 2018, Globenewswire.com published: “Entasis Therapeutics Initiates Global Phase 3 Pivotal Trial of ETX2514SUL for Patients with Carbapenem-Resistant Acinetobacter Infections – GlobeNewswire” on April 04, 2019. More interesting news about Entasis Therapeutics Holdings Inc. (NASDAQ:ETTX) were released by: Nasdaq.com and their article: “Entasis Therapeutics prices IPO below the range at $15; upsized offering yields $75 million – Nasdaq” published on September 25, 2018 as well as Globenewswire.com‘s news article titled: “Entasis Therapeutics Announces Multiple Data Presentations at ECCMID 2019 – GlobeNewswire” with publication date: April 10, 2019.

Receive News & Ratings Via Email - Enter your email address below to receive a concise daily summary of the latest news and analysts' ratings with our FREE daily email newsletter.